Abstracts tagged "fibromyalgia"

Abstract Number: LB03 • ACR Convergence 2025
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
Leslie Crofford¹, Dana Dailey², Barbara Van Gorp², Carol Vance², Andrew Post³, Ruth Chimenti², Ezgi Yarasir², Elizabeth Johnson¹, Kari Vance², Bridget Zimmerman², Fangfang Jiang², David-Erick Lafontant², Maxine Koepp², Dixie Ecklund², Emine Bayman² and Kathleen Sluka², ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²University of Iowa, Iowa City, Iowa, ³Grand Valley State University, Grand Rapids, Michigan
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain that is often exacerbated by movement. FM is associated with enhanced central pain transmission, while transcutaneous…
Abstract Number: 1244 • ACR Convergence 2025
PACFiND: Co-Designing Principles To Inform Reconfiguration Of Fibromyalgia Care Across Health Systems
Rosemary Hollick¹, Marcus Beasley¹, Ernest Choy², Caroline Cupit³, Debra Dulake¹, Teresa Finlay³, Louise Locock¹, Paul McNamee¹, Catherine Pope³, Elaine Wainwright¹, David Williams⁴ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University of Michigan, Michigan
Background/Purpose: Fibromyalgia is a contested and poorly supported condition, characterised by widespread pain, fatigue, and cognitive symptoms, often compounded by stigma and delayed diagnosis. Existing…
Abstract Number: 0197 • ACR Convergence 2025
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…
Abstract Number: 1242 • ACR Convergence 2025
Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Robert Katz¹, Alexandra Katz Small², Edwin Moore³ and Seth Adler⁴, ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, CHICAGO, IL, ³University of Illinois Urbana Champaign, CHICAGO, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a multifaceted disorder defined by chronic widespread pain, sleep disruption, fatigue, and cognitive difficulties. Although the predominant theory behind FM pathogenesis…
Abstract Number: 1243 • ACR Convergence 2025
Broad Cytokine Dysregulation in Fibromyalgia Patients: A Pilot Immune Profiling Study
Robert Katz¹ and Alexandra Katz Small², ¹Rush University Medical Center, Chicago, IL, ²Rheumatology Associates, CHICAGO, IL
Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, cognitive disturbances, and poor sleep. Despite accumulating evidence of immune involvement, a…
Abstract Number: 1237 • ACR Convergence 2025
Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
Michael Rosenbluth¹, Yifei Dai¹, Dianne Shumay¹ and Andrea Chadwick², ¹Swing Therapeutics, San Francisco, CA, ²University of Kansas School of Medicine, Kansas City, KS
Background/Purpose: Guidelines for fibromyalgia treatment recommend non-pharmacologic treatment, including cognitive behavioral therapy, alongside medications [1-3]. However, patient access to multi-modal treatment is frequently limited due…
Abstract Number: 1236 • ACR Convergence 2025
Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Michael Kaplan¹, Alexandra Canori², Rebecca Howard², Talia Torkian³, Rebecca Pietro¹, Gabriela Santiago-Pichardo¹, Daniel Clauw⁴, David Putrino², Yousaf Ali¹, Laura Tabacof² and Trung Ngo⁵, ¹Division of Rheumatology, Mount Sinai Hospital, New York, ²Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Icahn School of Medicine at Mount sinai, New York, ⁴Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁵RECOVER Injury Research Centre, The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Queensland, Australia
Background/Purpose: Fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are prototypical nociplastic disorders marked by centralized pain & fatigue, respectively. Nociplastic symptoms — such as…
Abstract Number: 1234 • ACR Convergence 2025
Serum Antibodies Against Glial Fibrillary Acidic Protein in Fibromyalgia: A Proof-of-Concept Study
Felipe Massó¹, Laura Aline Martinez-Martinez², Luis M Amezcua-Guerra³, Francisco Mercado⁴, Angélica Almanza⁵ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ²Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico, ³Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ⁴Instituto Nacional de Psiquiatría Ramón del la Fuente Muñiz, Mexico city, Mexico, ⁵Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico city, Mexico
Background/Purpose: Fibromyalgia (FM) is a stress-related disorder in which dorsal root ganglia (DRG) may play a pivotal pathogenetic role. DRG exhibit unique stress-induced, pro-algesic physio-anatomy,…
Abstract Number: 1231 • ACR Convergence 2025
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Gregory Sullivan¹, Errol Gould², Mary Kelley¹, Jean Engels¹ and Seth Lederman³, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceutical, Inc., Henderson, NV, ³Tonix Pharmaceuticals, Inc., Austin, TX
Background/Purpose: FDA-approved treatments for fibromyalgia (FM) have historically been limited by intolerable side effects that often lead to poor adherence. TNX-102 SL, a sublingual formulation…
Abstract Number: 1228 • ACR Convergence 2025
Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Brennan Spiegel¹, Jeffrey Curtis², Yashar Eshraghi³, Maged Guirguis³, Beth Darnall⁴, Christine Rini⁵, Emily Holladay⁶, Mehra Muskaan¹, So Yung Choi¹ and Samuel Eberlein¹, ¹Cedars Sinai, Los Angeles, CA, ²Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ³University of Queensland Ochsner Medical School, New Orleans, LA, ⁴Stanford University School of Medicine, Palo Alto, CA, ⁵Northwestern University, Chicago, IL, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evidence-based behavioral treatments for chronic pain are largely inaccessible, particularly to rural patients. This decentralized randomized controlled trial compared the effectiveness of two digital,…
Abstract Number: 2437 • ACR Convergence 2025
Bupropion for Lupus-Induced Fatigue Treatment (B-LIFT): A Retrospective Analysis
Aaron Smith¹, Thuyvan Phan², Leah Luizza³, Anthony Trujillo³, Becki Cleveland¹, Shruti Saxena Beem⁴, Tessa Englund⁵, Claire Timon⁴ and Saira Sheikh⁵, ¹University of North Carolina, Chapel Hill, NC, ²UNC Health, Chapel Hill, NC, ³University of North Carolina, Chapel Hill, ⁴University of North Carolina at Chapel Hill, Chapel Hill, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multi-system autoimmune disease with heterogenous presentation. Most patients with SLE report fatigue or brain fog, which often…
Abstract Number: 1226 • ACR Convergence 2025
Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome
Daniella Schocken¹, Mark Connelly², Sabrina Gmuca³, Andrea Ramirez⁴, Mary Ellen Riordan⁵, Tracy Ting⁶, Susmita Kashikar-Zuck⁷ and Jennifer Weiss⁸, ¹Children's Mercy Kansas City, Tampa, FL, ²Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, MO, ³Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Baylor College of Medicine, Houston, TX, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: Diagnosing juvenile fibromyalgia (JFM) in youth with chronic musculoskeletal (MSK) pain is challenging in the absence of a validated diagnostic tool. The Pain and…
Abstract Number: 2378 • ACR Convergence 2025
Factors Associated With Fatigue In Systemic Lupus Erythematosus: Data From The Almenara Lupus Cohort
Alvaro Oyarce-Calderón¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Samira Garcia-Hirsh⁴, Zoila Rodríguez-Bellido⁵, Cesar Pastor-Asurza⁶, Risto Perich-Campos⁷, Graciela Alarcón⁸ and Manuel Ugarte-Gil⁹, ¹Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁷Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide spectrum of clinical manifestations, fatigue being one of them; it is…
Abstract Number: 1225 • ACR Convergence 2025
Association between Anxiety and Tender Swollen Joint Difference in Patients with Rheumatoid Arthritis
Clarice Lin¹, Burcu Aydemir², Jing Song³, Lutfiyya muhammad², Clifton Bingham⁴, Tuhina Neogi⁵, Wendy Marder⁶, Marcy Bolster⁷, Daniel Clauw⁸, Dorothy Dunlop⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Worthington, MN, ⁴Johns Hopkins University, Baltimore, MD, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Michigan, Ann Arbor, MI, ⁷Massachusetts General Hospital, Concord, MA, ⁸Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ⁹Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Some patients with rheumatoid arthritis (RA) have pain, despite normalization of inflammatory markers and reduced swollen joint counts. Among these patients, the number of…
Abstract Number: 2189 • ACR Convergence 2025
Physician Practices and Perspectives in the Diagnosis and Management of Fibromyalgia: A US Chart Review Study
Daniel Clauw¹, Parul Houston², Zhao Yang², Todd Grinnell² and Lesley Arnold³, ¹Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ²Axsome Therapeutics, Inc, New York, NY, ³University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Fibromyalgia (FM) is a chronic, widespread pain disorder driven by dysregulated central pain processing, which impairs daily function and quality of life. Current understanding…

1
2
3
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].